Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial

Phlebology. 2023 Oct;38(9):622-627. doi: 10.1177/02683555231191969. Epub 2023 Jul 30.

Abstract

Objectives: This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS).

Methods: Women aged 18-70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5).

Results: A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25-4), STS 0.1% (3, 1.25-4), and STS 0.15% (4, 2-4) groups than in the HG group (4, 3-5) after 56 days, p = .00002.

Conclusion: Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS.

Trial registration: ClinicalTrials.gov NCT04132323.

Keywords: Telangiectasias; hypertonic glucose; sclerotherapy; sodium tetradecyl sulfate.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Female
  • Glucose Solution, Hypertonic
  • Humans
  • Prospective Studies
  • Sclerosing Solutions / therapeutic use
  • Sclerotherapy / methods
  • Sodium Tetradecyl Sulfate* / therapeutic use
  • Telangiectasis* / drug therapy

Substances

  • Sodium Tetradecyl Sulfate
  • Sclerosing Solutions
  • Glucose Solution, Hypertonic

Associated data

  • ClinicalTrials.gov/NCT04132323